Rain Oncology shares are trading lower after the company announced its Phase 3 MANTRA Trial of milademetan for the treatment of dedifferentiated liposarcoma did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Rain Oncology's Phase 3 MANTRA Trial of milademetan for the treatment of dedifferentiated liposarcoma did not meet its primary endpoint, causing its shares to trade lower.
May 22, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rain Oncology's stock price is trading lower due to the failure of its Phase 3 MANTRA Trial of milademetan in treating dedifferentiated liposarcoma.
The failure of the Phase 3 MANTRA Trial directly impacts Rain Oncology's stock price as it indicates that the company's product, milademetan, may not be as effective as previously thought. This could lead to a decrease in investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100